59 results about "Rectal Adenocarcinoma" patented technology

A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease. The disease may, for example, be a cancer such as breast cancer, lung fibrosis, colorectal adenocarcinoma, or the like. The apparatus may include in vivo instruments or laboratory diagnostic instruments with methods disclosed herein.

The present invention relates to in vitromethods and compositions for diagnosing and / or treating a colorectal adenocarcinoma associated with a chromosomal aberration on chromosome 20q and / or the predisposition for developing such an adenocarcinoma by determining the expression levels of a set of particular marker genes, wherein an elevated expression level of the marker genes in a test sample as compared to a control level is indicative of a colorectal adenocarcinoma.

The invention discloses a marker SLC26A9 for diagnosing and treating rectal adenocarcinoma. The experiment proves that the SLC26A9 is highly expressed in metastasis rectal adenocarcinoma tissues. The expression level of the SLC26A9 can be detected to predict the risk of rectal adenocarcinoma metastasis, diagnose the metastasis of the rectal adenocarcinoma and judge whether rectal adenocarcinoma relapses. The invention also discloses application of the SLC26A9 gene in preparing drugs for inhibiting / preventing metastasis of rectal adenocarcinoma.

The invention discloses an application of lncRNA in rectum adenocarcinoma diagnosis and treatment. lncRNA is LOC105374343. The invention first finds that the expression of LOC105374343 in rectum adenocarcinoma is obviously up-regulated, and a large sample test further proves that LOC105374343 can be used as a potential molecular target in rectum adenocarcinoma diagnosis and treatment. The invention also discloses the correlation between LOC105374343 and multiplication, migration and invasion of rectum adenocarcinoma cells and indicates that LOC105374343 can be used as the potential molecular target in clinic treatment of rectum adenocarcinoma.

The invention provides a nifurazide derivative and its preparation method and application, belonging to the field of chemical medicine. The structure of the nifurazide derivatives is shown in formula I. The nifurazide derivatives can effectively inhibit the proliferation of fibroblasts and the proliferation of human hepatic stellate cells, and most of the compounds have better inhibitory effects than nifurazide. The derivative can also reduce the proliferation of collagen fibers in the lung tissue of mice with pulmonary fibrosis, improve the interstitial fibrosis of mice, maintain the normal lung structure of mice, and even reverse the changes in lung structure of mice with pulmonary fibrosis. Humanized mice have good therapeutic effects and can be used to prepare candidate drugs for preventing and / or treating fibrosis. At the same time, the derivative has an excellent inhibitory effect on the proliferation of various tumor cells including breast cancer, colorectal adenocarcinoma, colon cancer and liver cancer, and can be used to prepare drug candidates for the prevention and / or treatment of various tumors. bright future.

Disclosed a saucernetin structurally simplified substance and the preparation method and pharmaceutical composition and use thereof. In particular, it relates to a compound of general formula (I) shown as formula (I) or an isomer thereof and a salt thereof, and the preparation method for such compounds. A novel pharmaceutical composition contains an effective amount of compound of formula I and a pharmacodynamically acceptable vector. The present invention also discloses the use of such compounds in preparing drugs for preventing and / or treating tumours. The tumours include neural glioblastoma, melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer and rectal adenocarcinoma.

The invention discloses a molecular marker for rectal adenocarcinoma diagnosis and treatment. The molecular mark is a SHROOM4 gene which is in a low-expression mode in tissue of a patient with rectal adenocarcinoma, and rectal adenocarcinoma apoptosis can be promoted by improving expression of SHROOM4. According to the molecular marker for the rectal adenocarcinoma diagnosis and treatment, sensibility and specificity of the rectal adenocarcinoma diagnosis are greatly improved, and meanwhile a new target site is provided for a gene therapy of the rectal adenocarcinoma.

Applications of LINC00540 in rectal adenocarcinoma diagnosis and treatment are disclosed. Whether a patient suffers from rectal adenocarcinoma or not is determined through detecting the expression level of the LINC00540. Rectal adenocarcinoma cell proliferation, migration and invasion can be suppressed through lowering the expression level of the LINC00540, thus providing molecular means for rectal adenocarcinoma treatment.

The invention discloses a molecular marker related to genesis and development of rectum adenocarcinoma. A high-throughput sequencing technology and bioinformatics are combined to screen IncRNA representing differential expression in the tissue of rectum adenocarcinoma, which firstly discovers that LOC105373485 represents differential expression in the tissue of rectum adenocarcinoma, furthermore,large sample verification and cell experiments prove that the IncRNA is related to proliferation, migration and invasion of rectum adenocarcinoma.

The invention discloses a gene HRNBP3 and new application of an expression product of the gene HRNBP3 in diseases, and particularly relates to the gene HRNBP3 and application of the expression product of the gene HRNBP3 in diagnosis and treatment of the rectal adenocarcinoma. The invention further discloses application of the gene HRNBP3 in preparation of a product for diagnosing the rectal adenocarcinoma, and meanwhile discloses application of the gene HRNBP3 in preparation of medicine for treating the rectal adenocarcinoma.